Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17500003 | 0.78 | HPGD (0.51) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11621982 | 0.75 | HPGD (0.49) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28865979 | 0.74 | NPC1 (0.48) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4659012 | 0.74 | L3MBTL1 (0.69) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3111473 | 0.73 | NPC1 (0.58) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6697261 | 0.73 | NPC1 (0.58) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6176204 | 0.73 | NPC1 (0.57) | HPGDALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL1848870 | 0.73 | NPC1 (0.48) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19151267 | 0.73 | HPGD (0.52) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3390876 | 0.73 | ALDH1A1 (0.57) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1917244-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022964-A2 | HETARYL-SUBSTITUTED GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5-RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-0792291-B1 | PROTEIN AFFECTING KATP CHANNELS | UPJOHN CO (US) | 2000-09-20 | — | — | EP | disclosed |
| US-5925742-A | GLYCOPROTEIN OF 54,000 TO 60,000 DALTONS FROM RAT CELLS AND CAPABLE OF BINDING N-(3-AZIDO-5-IODOPHENYL)-N'-CYANO-N''-(1,1-DIMETHYLPROPYL)-GUANIDINE; MODULATORS OF ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNELS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5856449-A | GLYCOPROTEIN | PHARMACIA & UPJOHN COMPANY (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0792291-A1 | PROTEIN AFFECTING KATP CHANNELS | PHARMACIA & UPJOHN COMPANY (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996016088-A1 | PROTEIN AFFECTING KATP CHANNELS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | HPGD 1026/4885ALDH1A1 1066/4885NPC1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.